Founded in 2016 as a University of Tokyo venture, Nanotis has been researching and developing next-generation rapid testing devices with the mission of "providing quick and accurate Notices to all people fighting against diseases. The first target is influenza, and the company aims to realize a highly sensitive test that does not require specialized technology to meet the needs of the medical field.
In order to prevent the spread of infectious diseases, it is important to realize early testing, treatment, and rapid response such as patient isolation. The recent outbreak of the new coronavirus has renewed awareness of the importance of rapid, simple, and highly sensitive screening tests. The elemental technologies being developed by Nanotis are platform technologies that can be applied to a wide variety of fields, including infectious diseases other than influenza and food testing. In the future, the company plans to promote the construction of innovative healthcare systems with the aim of applying this technology to primary screening tests outside of medical institutions, such as in private homes, in collaboration with telemedicine, and in epidemiological studies on a global scale.
With the investment from Taisho Pharmaceutical, which has strengths in both the self-medication and pharmaceutical businesses, the company will continue to promote research and development to establish elemental technologies, strengthen recruitment of core human resources such as engineers and management personnel, and further expand its business.
The current fundraising is positioned as the first round of the pre-series A round, and the company will continue to raise funds from institutional and individual investors.
| name of company | Nanotis Corporation |
| Establishment | June 6, 2016 |
| Location | 5-50-13 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan |
| representative | CEO, Founder: Risa Sakashita |
| Business Overview | Research and development of rapid testing devices |
| uniform resouce locator | http://nanotis.net/ |






